Prestige BioPharma Limited (KRX:950210)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,020
-190 (-1.44%)
At close: Oct 2, 2025
-1.44%
Market Cap156.49B
Revenue (ttm)14.33B
Net Income (ttm)22.30B
Shares Out12.02M
EPS (ttm)370.20
PE Ratio35.17
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume125,683
Average Volume127,745
Open13,210
Previous Close13,210
Day's Range12,830 - 13,320
52-Week Range11,000 - 20,900
Beta1.04
RSI35.21
Earnings DateSep 19, 2025

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Singapore
Stock Exchange Korea Stock Exchange
Ticker Symbol 950210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.